Intestal

Bismuth subsalicylate, the active ingredient in Intestal, is an antidiarrheal presented as an oral formulation for oral use and available over‑the‑counter. It is employed to relieve diarrhea, nausea, heartburn, indigestion and gastritis in adults and children when appropriate.

GNH USA supplies Intestal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality and regulatory standards for global distribution.

Intestal (bismuth subsalicylate) is used to manage gastrointestinal disturbances that involve excess fluid secretion or irritation.

- Diarrhea: reduces stool frequency and liquidity by adsorbing toxins and bacteria. - Nausea: soothes stomach lining and diminishes nausea sensations. - Heartburn: provides antacid action that neutralises excess gastric acid. - Indigestion: coats the mucosa to alleviate discomfort after meals. - Gastritis: diminishes inflammation and protects irritated gastric tissue.

Intestal may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Darkened tongue or mouth lining. - Blackened stools. - Constipation. - Nausea. - Abdominal discomfort.

Serious or Rare Side Effects: - Allergic reactions such as rash, swelling or difficulty breathing. - Severe constipation leading to bowel obstruction. - Persistent black discoloration of the oral cavity. - Blood in stool. - Rare cases of Stevens‑Johnson syndrome.

Before using Intestal, consider the following safety measures.

- Pregnancy: consult a healthcare professional as safety has not been established. - Breastfeeding: avoid unless advised by a clinician. - Renal impairment: use with caution and monitor renal function. - Concurrent salicylate therapy: increased risk of salicylate toxicity. - Known hypersensitivity: do not use if allergic to bismuth or salicylates. - Store at room temperature: keep in the original container, protect from moisture and heat.

Intestal can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Methotrexate: potential for heightened toxicity. - Tetracycline antibiotics: reduced absorption of both agents.

Moderate Interactions (Monitor Closely): - Other antacids: may alter gastric pH and affect coating action. - Iron supplements: may diminish efficacy of bismuth subsalicylate. - Proton pump inhibitors: could affect the drug's protective coating function.